Bliss GVS Pharma Q3 results, Rs 0.50 interim dividend declared

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹202.50

prior close

₹208.48

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%-0.0% vs market

Pharmaceuticals peers, median of 159sector+0.4%+0.6% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

-0.8

15m

-1.3

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0+1.0-0.0+0.4+0.6

Next day

+5.9+0.5+5.4+0.2+5.7

+7.6-0.0+7.6-0.0+7.6

+6.7-1.5+8.2-1.2+7.9

+9.1-2.2+11.3-1.8+10.9

+14.3-1.2+15.5-1.8+16.1

+11.6-2.4+14.0-2.6+14.2

15d

+6.7-8.8+15.5-7.0+13.7

+9.9-8.3+18.2-5.1+15.0

+27.9-3.5+31.4-3.5+31.4

+34.8+6.4+28.4+2.8+32.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q3 FY26 results and declared Rs 0.50 per share interim dividend (50 percent on Re 1 face value). Record date Feb 18, 2026. Consolidated 9M revenue rose about 24.5 percent to Rs 670 crore, with PAT up around 71 percent. Standalone 9M revenue grew modestly. Exceptional charge of Rs 2.51 crore taken for new Labour Codes.

Likely market impact

Modest dividend plus strong consolidated growth. Watch for sustainability given one-off charges and Nigeria subsidiary deconsolidation.